Clinical trial

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy

NCT01859741

Study summary

ClinicalTrials.gov

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention OMP-59R5 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Etoposide Normalized identity: etoposide View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Cisplatin or Carboplatin Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2012-01-07

PhasePHASE1 / PHASE2

Conditions

Stage IV Small Cell Lung Cancerunresolved

Interventions

OMP-59R5DRUG

EtoposideDRUG · verified · RxNorm: etoposide

PlaceboDRUG

Cisplatin or CarboplatinDRUG

Sponsors & collaborators

OncoMed Pharmaceuticals, Inc.lead sponsor

Mapped research locations

BaltimoreMaryland, United States3 AtlantaGeorgia, United States2 New YorkNew York, United States1 HoustonTexas, United States1 ChicagoIllinois, United States1 Los AngelesCalifornia, United States1 DallasTexas, United States1 San AntonioTexas, United States1 NashvilleTennessee, United States1 SeattleWashington, United States1 ClevelandOhio, United States1 PittsburghPennsylvania, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01859741 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.